Julia Emerson

Summary

Affiliation: Children's Hospital and Regional Medical Center
Country: USA

Publications

  1. ncbi Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Julia Emerson
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, USA
    Pediatr Pulmonol 34:91-100. 2002
  2. ncbi Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
  3. ncbi Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
  4. ncbi Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
  5. ncbi Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
  6. ncbi Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression
    Lucas R Hoffman
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Cyst Fibros 8:66-70. 2009
  7. ncbi Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
    Pediatr Pulmonol 42:610-23. 2007
  8. ncbi Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008
    Julia Emerson
    Seattle Children s Hospital, Seattle, Washington 98101, USA
    Pediatr Pulmonol 45:363-70. 2010
  9. ncbi Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, WA 98105, USA
    J Cyst Fibros 11:456-7. 2012
  10. ncbi Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 167:841-9. 2003

Detail Information

Publications19

  1. ncbi Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Julia Emerson
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, USA
    Pediatr Pulmonol 34:91-100. 2002
    ..These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention...
  2. ncbi Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
    ..Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood...
  3. ncbi Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
    ..The EPIC Observational Study is an ongoing prospective cohort study investigating risk factors for and clinical outcomes associated with early Pseudomonas aeruginosa (Pa) acquisition in young children with cystic fibrosis (CF)...
  4. ncbi Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
    ..To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF)...
  5. ncbi Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
    ..We aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations...
  6. ncbi Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression
    Lucas R Hoffman
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Cyst Fibros 8:66-70. 2009
    ..Pseudomonas aeruginosa with mutations in the transcriptional regulator LasR chronically infect the airways of people with cystic fibrosis (CF), yet the prevalence and clinical implications of lasR mutant infection are unknown...
  7. ncbi Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
    Pediatr Pulmonol 42:610-23. 2007
    ..Early intervention strategies include tobramycin solution for inhalation (TSI), which can eradicate lower airway Pa from cultures obtained at the end of 28 days of treatment in young children...
  8. ncbi Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008
    Julia Emerson
    Seattle Children s Hospital, Seattle, Washington 98101, USA
    Pediatr Pulmonol 45:363-70. 2010
    ..The study objective was to identify changes in cystic fibrosis (CF) sputum microbiology over 13 years...
  9. ncbi Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care
    Margaret Rosenfeld
    Division of Pulmonary Medicine, Seattle Children s Hospital, Seattle, WA 98105, USA
    J Cyst Fibros 11:456-7. 2012
    ..To describe the prevalence of the CF pathogens Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae in OP cultures from healthy children...
  10. ncbi Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 167:841-9. 2003
    ..We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis...
  11. ncbi Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings
    Jane L Burns
    Department of Pediatrics, Division of Infectious Diseases, University of Washington and Seattle Children s Hospital, USA
    Influenza Other Respi Viruses 6:218-23. 2012
    ..In addition, associations between viral detection and respiratory symptoms are not well described...
  12. ncbi Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, and Division of Pulmonary Medicine, Children's Hospital and Regional Medical Center, Seattle, USA
    J Clin Microbiol 42:1915-22. 2004
    ....
  13. ncbi Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors
    Christine L Halbert
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
    Hum Gene Ther 17:440-7. 2006
    ..AAV5-positive sera were lower both in titers and rates than those seen for AAV6. The results indicate that AAV type 2, 5 or 6 exposure is low in CF and control populations and even lower in CF children...
  14. ncbi Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis
    Mary J Emond
    Department of Biostatistics, University of Washington, Seattle, Washington, USA
    Nat Genet 44:886-9. 2012
    ..aeruginosa airway infection, chronic P. aeruginosa infection and mucoid P. aeruginosa in individuals with cystic fibrosis...
  15. ncbi Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:19890-5. 2006
    ....
  16. ncbi Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis
    Xuan Qin
    Department of Laboratory Medicine, Therapeutics Development Network Resource Center for Microbiology, Children's Hospital and Regional Medical Center, University of Washington, Seattle, Washington, USA
    J Clin Microbiol 41:4312-7. 2003
    ..Given the diversity of these CF isolates, real-time PCR with a combination of two target sequences appears to be the optimum choice for identification of atypical P. aeruginosa and for non-P. aeruginosa gram-negative isolates...
  17. ncbi Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 166:1550-5. 2002
    ..Better clinical predictors of short-term mortality among patients with CF are needed...
  18. ncbi Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials
    Thomas A Standaert
    University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 37:385-92. 2004
    ..Valid and consistent results can be attained with trained operators and attention to technical details. These data demonstrate the procedure to be sufficient for multicenter studies in the CF Foundation network...
  19. ncbi Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study
    Mark Dovey
    Section of Pediatric Pulmonology and Allergy, St Christopher s Hospital For Children, Philadelphia, PA, USA
    Chest 132:1212-8. 2007
    ..We hypothesized that adding 5 days of prednisone to standard therapy for acute pulmonary exacerbations in patients with cystic fibrosis (CF) would result in a more rapid and greater increase in lung function...